Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

15.49EUR
11:35am EDT
Change (% chg)

€-0.02 (-0.13%)
Prev Close
€15.51
Open
€15.53
Day's High
€15.55
Day's Low
€15.40
Volume
132,517
Avg. Vol
187,861
52-wk High
€18.00
52-wk Low
€10.83

Latest Key Developments (Source: Significant Developments)

Almirall Announces Re-Designation 250 Mln Euro Senior Unsecured Conditionally Convertible Bonds Due 2021 As Convertible And/Or Exchangeable Bonds
Monday, 17 Jun 2019 02:00am EDT 

June 17 (Reuters) - Almirall SA ::ANNOUNCES RE-DESIGNATION 250 MILLION EURO SENIOR UNSECURED CONDITIONALLY CONVERTIBLE BONDS DUE 2021 AS CONVERTIBLE AND/OR EXCHANGEABLE BONDS.NEW ISSUE REQUIREMENTS HAVE BEEN SATISFIED AND BONDS HAVE BEEN RE-DESIGNATED WITH EFFECT FROM JUNE 25 2019.  Full Article

Almirall To Make Decision Regarding Exercise Of Its Lebrikizumab Option By Mid-Year
Monday, 3 Jun 2019 02:10am EDT 

June 3 (Reuters) - Almirall SA ::TO MAKE DECISION REGARDING EXERCISE OF OPTION TO EXCLUSIVELY LICENSE RIGHTS TO DEVELOP AND COMMERCIALIZE LEBRIKIZUMAB IN EUROPE BY MID-YEAR.IF ALMIRALL ELECTS TO EXERCISE ITS OPTION, COMPANY WILL PAY DERMIRA AN OPTION EXERCISE FEE OF $50 MILLION.  Full Article

Almirall To Pay Scrip Dividend Of 0.198 Euros Gross/Right
Wednesday, 8 May 2019 01:14pm EDT 

May 9 (Reuters) - Almirall SA ::SAID ON WEDNESDAY IT WOULD INCREASE SHARE CAPITAL BY ISSUING 2.3 MILLION SHARES FOR ITS SCRIP DIVIDEND PROGRAM .SHAREHOLDERS WILL BE ENTITLED TO RECEIVE ONE NEW SHARE FOR EACH 74 SHARES PREVIOUSLY HELD.THE PRICE OF THE COMMITMENT TO PURCHASE RIGHTS ASSUMED BY ALMIRALL IS 0.198 EUROS GROSS PER RIGH, TO BE PAID ON JUNE 3.  Full Article

Almirall: NICE In UK Gives Final Recommendation For Co's Drug To Treat Plaque Psoriasis
Thursday, 18 Apr 2019 05:41am EDT 

April 18 (Reuters) - Almirall SA ::SAID ON WEDNESDAY THAT NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) IN UK HAD PUBLISHED ITS FINAL RECOMMENDATION FOR ILUMETRI (TILDRAKIZUMAB) AS A COST-EFFECTIVE OPTION TO TREAT MODERATE-TO-SEVERE PLAQUE PSORIASIS .TILDRAKIZUMAB WAS APPROVED BY THE EUROPEAN COMMISSION IN SEPTEMBER 2018, IS ALREADY AVAILABLE IN GERMANY AND IS DUE TO BE MARKETED IN ALL EU MEMBER STATES.ILUMETRI RECEIVED A PROVISIONAL APPROVAL FROM NICE ON MARCH 8.  Full Article

Hitgen, Almirall Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
Monday, 25 Mar 2019 03:30am EDT 

March 25 (Reuters) - ALMIRALL SA ::HITGEN AND ALMIRALL ENTER DNA-ENCODED LIBRARY BASED INNOVATIVE DRUG DISCOVERY RESEARCH COLLABORATION.HITGEN LTD ANNOUNCED THAT THE COMPANY HAS ENTERED INTO A RESEARCH COLLABORATION WITH ALMIRALL TO IDENTIFY NOVEL SMALL MOLECULE LEADS FOR TARGETS OF INTEREST.SPECIFIC FINANCIAL DETAILS WERE NOT DISCLOSED.  Full Article

NICE Provisionally Approves Almirall's Ilumetri For Adults With Plaque Psoriasis In UK
Friday, 8 Mar 2019 06:36am EST 

March 8 (Reuters) - Almirall SA ::NICE PROVISIONALLY APPROVES ILUMETRI AS COST EFFECTIVE OPTION FOR ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN UK.  Full Article

Almirall Enters Into Definitive Agreement To Divest ThermiGen
Monday, 4 Mar 2019 02:02am EST 

March 4 (Reuters) - Almirall SA ::SAYS ENTERS INTO DEFINITIVE AGREEMENT TO DIVEST THERMIGEN, ITS MEDICAL DEVICE AESTHETICS BUSINESS.SIGNS DEAL WITH CELLING BIOSCIENCES FOR THERMIGEN, TRANSACTION IS EXPECTED TO CLOSE BEFORE OR ON MARCH 29.SAYS TRANSACTION DOES NOT AFFECT ALMIRALL GUIDANCE FOR 2019.  Full Article

Almirall-Nuevolution Partnership Achieves First Collaboration Milestone For Dermatology Diseases
Thursday, 28 Feb 2019 05:06am EST 

Feb 28 (Reuters) - Almirall SA ::ALMIRALL-NUEVOLUTION PARTNERSHIP ACHIEVES FIRST COLLABORATION MILESTONE FOR DERMATOLOGY DISEASES.THE POSITIVE RESULT TRIGGERED A CONTRACTUAL MILESTONE TO NUEVOLUTION.MILESTONE DATA ACHIEVED SUPPORTS A PROGRAM WITH A CANDIDATE DRUG HAVING BEST-IN-CLASS POTENTIAL.  Full Article

Almirall FY Net Result Swings To Profit Of 77.7 Mln Euros
Monday, 25 Feb 2019 01:05am EST 

Feb 25 (Reuters) - Almirall SA ::FY EBITDA 209.5 MILLION EUROS VERSUS 142.2 MILLION EUROS YEAR AGO.FY NORMALIZED NET PROFIT 88.2 MILLION EUROS VERSUS 27.1 MILLION EUROS YEAR AGO.FY REVENUE 811.0 MILLION EUROS VERSUS 755.8 MILLION EUROS YEAR AGO.2019 GUIDANCE : TOTAL REVENUES TO GROW AT LOW DOUBLE-DIGIT AND EBITDA TO REACH €290-€300 MILLION (VERSUS. 2018).FY RESEARCH AND DEVELOPMENT EXPENSES 87.6 MILLION EUROS VERSUS 87.9 MILLION EUROS YEAR AGO.FY NET PROFIT 77.7 MILLION EUROS VERSUS LOSS 304.0 MILLION EUROS YEAR AGO.  Full Article

Almirall H1 Net Result Turns To Profit Of 52 Mln Euros YoY
Monday, 30 Jul 2018 01:42am EDT 

July 30 (Reuters) - Almirall SA ::H1 NET PROFIT 52.0 MILLION EUROS VERSUS LOSS 73.1 MILLION EUROS YEAR AGO.H1 EBITDA 105.5 MILLION EUROS VERSUS 58.6 MILLION EUROS YEAR AGO.H1 REVENUE 398.3 MILLION EUROS VERSUS 378.9 MILLION EUROS YEAR AGO.UPGRADES 2018 EBITDA GUIDANCE, NOW SEES YOY GROWTH C. 30% VERSUS ORIGINAL EBITDA FORECAST OF C. 20% GROWTH.CONFIRMS TOTAL REVENUE GUIDANCE FOR 2018.SEES DECLINE IN SALES AT THERMIGEN, DUE TO EARLY TERMINATION OF INSTALIFTTM AGREEMENT AND POOR PERFORMANCE OF CAPITAL SALES.  Full Article

Drugmaker Almirall settles kickback allegations for $6.6 million

Spanish drugmaker Almirall has agreed to pay $6.6 million to resolve claims that its U.S. unit paid kickbacks to incentivize doctors to prescribe its dermatology products, the U.S. Justice Department and lawyers for a whistleblower said on Wednesday.